SANUWAVE Health Reports Record Q4 & Full-Year 2025 Revenue, Returns to Profitability, and Issues Strong 2026 Guidance

summarizeSummary

SANUWAVE Health announced record revenues for Q4 and full-year 2025, a significant turnaround to net income, and provided robust revenue guidance for 2026, following a prior non-reliance notice on financial statements.

check_boxKey Events

• Record Revenue Achieved

  Reported record Q4 2025 revenue of $13.4 million (up 29.7%) and record full-year 2025 revenue of $44.1 million (up 35%).

• Return to Profitability

  Swung from a net loss of $33.1 million in 2024 to a net income of $11.8 million in 2025, driven by operating profit and changes in derivative liabilities.

• Strong Adjusted EBITDA Growth

  Adjusted EBITDA for the full year 2025 increased significantly to $13.6 million, up from $7.2 million in 2024.

• Positive 2026 Revenue Guidance

  Forecasts Q1 2026 revenue of $9.6-$10.3 million and initiates full-year 2026 revenue guidance of $51.0-$55.0 million, representing 16-25% growth.

auto_awesomeAnalysis

This 8-K filing is highly important as it addresses the prior non-reliance notice from March 13, 2026, by providing restated and strong financial results for Q4 and the full year 2025. The company achieved record quarterly and annual revenues, with full-year revenue increasing 35% to $44.1 million. Critically, SANUWAVE Health swung from a substantial net loss in 2024 to a net income of $11.8 million in 2025, alongside a near doubling of Adjusted EBITDA. The positive momentum is expected to continue with strong revenue guidance for 2026, projecting 16-25% growth. This comprehensive positive financial update, especially while the stock is trading near its 52-week low, could significantly boost investor confidence and re-establish financial transparency after recent accounting concerns.